| __timestamp | Amphastar Pharmaceuticals, Inc. | GSK plc |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 8246000000 |
| Thursday, January 1, 2015 | 46974000 | 9232000000 |
| Friday, January 1, 2016 | 47298000 | 9366000000 |
| Sunday, January 1, 2017 | 50918000 | 9672000000 |
| Monday, January 1, 2018 | 58044000 | 9915000000 |
| Tuesday, January 1, 2019 | 63109000 | 11402000000 |
| Wednesday, January 1, 2020 | 65157000 | 11456000000 |
| Friday, January 1, 2021 | 68920000 | 10975000000 |
| Saturday, January 1, 2022 | 66592000 | 8372000000 |
| Sunday, January 1, 2023 | 80393000 | 9385000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of GSK plc and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, GSK plc consistently outspent Amphastar, with SG&A expenses peaking at approximately $11.5 billion in 2020. In contrast, Amphastar's expenses showed a steady increase, reaching around $80 million in 2023, marking a 99% rise from 2014. This trend highlights GSK's expansive operational scale compared to Amphastar's more conservative growth. Notably, GSK's expenses dipped by 27% in 2022, reflecting potential strategic shifts or market conditions. These insights offer a window into the financial dynamics and strategic priorities of these pharmaceutical giants, providing valuable context for investors and industry analysts alike.
Breaking Down SG&A Expenses: GSK plc vs ADMA Biologics, Inc.
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
GSK plc and Merus N.V.: SG&A Spending Patterns Compared
GSK plc vs Amphastar Pharmaceuticals, Inc.: Examining Key Revenue Metrics
Comparing SG&A Expenses: GSK plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.